NCT04170946 Talazoparib and Thoracic RT for ES-SCLC
| NCT ID | NCT04170946 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University Health Network, Toronto |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2020-10-05 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2020-10-05 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a phase I, dose escalating study evaluating the safety of combining talazoparib and low dose consolidative thoracic radiotherapy for small cell lung cancer patients. This study will also determine the maximum tolerated dose (MTD) of talazoparib in combination with low dose thoracic radiotherapy. Patients will start on talazoparib on day 1 of study intervention, and will continue to orally take talazoparib until the last day of radiation therapy. Up to 24 patients will be enrolled to the study, where the first 3 patients will start with a starting dose level of talazoparib is 0.5 mg PO once daily. This will increase to 1mg daily with each new cohort.
Eligibility Criteria
Inclusion Criteria: * Histological documented diagnosis of SCLC confirmed by a UHN pathologist. * Documented extensive disease * Completion of induction chemotherapy, 4-6 cycles of a platinum agent and etoposide. * No disease progression (i.e.SD or better response by RECIST 1.1) at the completion of chemotherapy. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnosfsky Performance Score (KPS) ≥50; see Appendix B). * Adequate organ and marrow function, * Postmenopausal or evidence of non-childbearing status for women of childbearing potential negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1. Exclusion Criteria: * Untreated brain metastases. * Previous radiotherapy to thorax (prior breast RT is permitted). * Patients receiving any systemic chemotherapy, radiotherapy or immunotherapy (except for standard of care treatments or palliative reasons) within 3 weeks prior to study treatment. * Exposure to an investigational product within 30 days or 5 half-lives (whichever is longer) prior to start of the current study drug. * Any previous treatment with PARP inhibitor, including talazoparib. * Concomitant use of strong P-gp inhibitors * Concomitant use of other known P-gp inhibitors, P-gp inducers, or BCRP inhibitors * Persistent toxicities (\>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia. * Patients with myelodysplastic syndrome/acute leukaemia or with features suggestive thereof. * Major surgery within 2 weeks of study treatment initiation and patients must have recovered from any effects of any major surgery. * Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active/uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent * Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication. * Immunocompromised patients, * Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT). * Whole blood transfusions in the last 120 days prior to entry to the study * Other malignancy within the last 5 years * Patients with spinal cord compression
Contact & Investigator
Benjamin Lok, MD
PRINCIPAL INVESTIGATOR
Princess Margaret Cancer Center
Frequently Asked Questions
Who can join the NCT04170946 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04170946 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT04170946 currently recruiting?
Yes, NCT04170946 is actively recruiting participants. Contact the research team at Benjamin.Lok@rmp.uhn.ca for enrollment information.
Where is the NCT04170946 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT04170946 clinical trial?
NCT04170946 is sponsored by University Health Network, Toronto. The principal investigator is Benjamin Lok, MD at Princess Margaret Cancer Center. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.